METHODS FOR TREATING SCHIZOPHRENIA
The disclosure provides methods for treating psychiatric diseases, such as schizophrenia, in patients with certain gene polymorphisms using antipsychotic drugs, such as risperidone and paliperidone.
1 . A method of treating schizophrenia without use of an oral risperidone medication in a patient in need thereof, the method comprising subcutaneously administering to the patient a therapeutically effective amount of a risperidone composition without administration of the oral risperidone medication; wherein the risperidone composition comprises about 90 mg or about 120 mg of risperidone base at a concentration of about 15 wt %; about 38 wt % of a poly(lactide-co-glycolide)copolymer; and about 47 wt % N-methyl-2-pyrrolidone.
2 . The method of claim 1 , wherein poly(lactide-co-glycolide)copolymer is an 80:20 poly(lactide-co-glycolide)copolymer having a number average molecular weight from about 20,000 Daltons to about 30,000 Daltons.
3 . The method of claim 1 , wherein the risperidone composition comprises about 90 mg of risperidone base.
4 . The method of claim 1 , wherein the risperidone composition comprises about 120 mg of risperidone base.
5 . A method to produce therapeutic concentrations of risperidone and 9-hydroxyrisperidone after a first injection of a risperidone composition without use of an oral risperidone medication in a schizophrenic patient in need thereof, the method comprising subcutaneously injecting the patient with the risperidone composition without administration of the oral risperidone medication; wherein the risperidone composition comprises about 90 mg or about 120 mg of risperidone base at a concentration of about 15 wt %; about 38 wt % of a poly(lactide-co-glycolide)copolymer; and about 47 wt % N-methyl-2-pyrrolidone.
6 . The method of claim 5 , wherein poly(lactide-co-glycolide)copolymer is an 80:20 poly(lactide-co-glycolide)copolymer having a number average molecular weight from about 20,000 Daltons to about 30,000 Daltons.
7 . The method of claim 5 , wherein the risperidone composition comprises about 90 mg of risperidone base.
8 . The method of claim 5 , wherein the risperidone composition comprises about 120 mg of risperidone base.
9 . A method of treating schizophrenia without use of a supplemental risperidone medication in a patient in need thereof, the method comprising subcutaneously administering to the patient a therapeutically effective amount of a risperidone composition without administration of the supplemental risperidone medication; wherein the risperidone composition comprises about 90 mg or about 120 mg risperidone base at a concentration of about 10 wt % to about 20 wt %; about 25 wt % to about 50 wt % of a poly(lactide-co-glycolide) copolymer; and about 35 wt % to about 60 wt % of N-methyl-2-pyrrolidone.
10 . The method of claim 9 , wherein the supplemental risperidone medication is an injectable risperidone medication.
11 . The method of claim 9 , wherein the supplemental risperidone medication is an oral risperidone medication.
12 . The method of claim 9 , wherein the composition comprises 90 mg of risperidone base at a concentration of about 15 wt %; about 38 wt % of a 50:50 to 90:10 poly(lactide-co-glycolide)copolymer; and about 47 wt % N-methyl-2-pyrrolidone.
13 . The method of claim 12 , wherein the 50:50 to 90:10 poly(lactide-co-glycolide) copolymer is an 80:20 poly(lactide-co-glycolide) copolymer.
14 . The method of claim 13 , wherein the poly(lactide-co-glycolide) copolymer has a weight average molecular weight from about 20,000 Daltons to about 30,000 Daltons.
15 . The method of claim 9 , wherein the composition comprises 120 mg of risperidone base at a concentration of about 15 wt %; about 38 wt % of a 50:50 to 90:10 poly(lactide-co-glycolide)copolymer; and about 47 wt % N-methyl-2-pyrrolidone.
16 . The method of claim 15 , wherein the 50:50 to 90:10 poly(lactide-co-glycolide) copolymer is an 80:20 poly(lactide-co-glycolide) copolymer.
17 . The method of claim 16 , wherein the poly(lactide-co-glycolide) copolymer has a weight average molecular weight from about 20,000 Daltons to about 30,000 Daltons.
18 . The method of claim 9 , comprising subcutaneously administering the risperidone composition once per month.
19 . A method to produce therapeutic concentrations of risperidone and 9-hydroxyrisperidone after a first injection of a risperidone composition without use of a supplemental risperidone medication in a patient in need thereof, the method comprising subcutaneously administering to the patient a therapeutically effective amount of a risperidone composition without administration of the supplemental risperidone medication; wherein the risperidone composition comprises about 90 mg or about 120 mg risperidone base at a concentration of about 10 wt % to about 20 wt %; about 25 wt % to about 50 wt % of a poly(lactide-co-glycolide) copolymer; and about 35 wt % to about 60 wt % of N-methyl-2-pyrrolidone.
20 . The method of claim 19 , wherein the supplemental risperidone medication is an injectable risperidone medication.
21 . The method of claim 19 , wherein the supplemental risperidone medication is an oral risperidone medication.
22 . The method of claim 19 , wherein the composition comprises 90 mg of risperidone base at a concentration of about 15 wt %; about 38 wt % of a 50:50 to 90:10 poly(lactide-co-glycolide)copolymer; and about 47 wt % N-methyl-2-pyrrolidone.
23 . The method of claim 22 , wherein the 50:50 to 90:10 poly(lactide-co-glycolide) copolymer is an 80:20 poly(lactide-co-glycolide) copolymer.
24 . The method of claim 23 , wherein the poly(lactide-co-glycolide) copolymer has a weight average molecular weight from about 20,000 Daltons to about 30,000 Daltons.
25 . The method of claim 19 , wherein the composition comprises 120 mg of risperidone base at a concentration of about 15 wt %; about 38 wt % of a 50:50 to 90:10 poly(lactide-co-glycolide)copolymer; and about 47 wt % N-methyl-2-pyrrolidone.
26 . The method of claim 25 , wherein the 50:50 to 90:10 poly(lactide-co-glycolide) copolymer is an 80:20 poly(lactide-co-glycolide) copolymer.
27 . The method of claim 26 , wherein the poly(lactide-co-glycolide) copolymer has a weight average molecular weight from about 20,000 Daltons to about 30,000 Daltons.